Diamyd Medical’s Diamyd (rhGAD65/alum) has been granted with FTD by the US FDA for improving glycemic control in recently diagnosed patients with stage 3 Type 1 diabetes having genotype HLA DR3-DQ2
The company is investigating Diamyd in the P-III (DIAGNODE-3) study for its safety and efficacy in patients (n=330; 12yrs. to 29yrs.) diagnosed with Type 1 Diabetes having HLA DR3-DQ2 genotype
Diamyd, in studies, has demonstrated the ability to safely modulate the immune system targeting pancreatic beta cells to stop or slow the disease progression
Ref: Diamyd Medical | Image: Diamyd Medical
Related News:- Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
